Home > Boards > US Listed > Medical - Equipment > Milestone Scientific Inc. (MLSS)

Milestone Scientific Provides Business Update for the Second

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
swanlinbar Member Profile
 
Followed By 64
Posts 10,089
Boards Moderated 8
Alias Born 08/09/00
160x600 placeholder
Prospectus Filed Pursuant to Rule 424(b)(2) (424b2) Edgar (US Regulatory) - 5/20/2019 2:17:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/17/2019 10:40:45 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 5/17/2019 6:01:14 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/14/2019 4:35:08 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 5/2/2019 4:20:51 PM
Amended Statement of Beneficial Ownership (3/a) Edgar (US Regulatory) - 4/15/2019 4:44:39 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/15/2019 2:23:09 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/11/2019 3:07:31 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/11/2019 11:54:16 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/9/2019 6:03:27 AM
Annual Report (10-k) Edgar (US Regulatory) - 4/1/2019 4:20:46 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/26/2019 5:20:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/26/2019 5:19:33 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/14/2019 8:47:12 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/8/2019 12:38:28 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 2/8/2019 12:37:32 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 2/1/2019 4:22:18 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/1/2019 8:53:21 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 1/31/2019 5:23:52 PM
Milestone Scientific Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire Inc. - 1/31/2019 4:21:17 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 1/25/2019 5:44:46 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/23/2018 4:48:56 PM
Amended Quarterly Report (10-q/a) Edgar (US Regulatory) - 11/16/2018 4:00:32 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/14/2018 4:37:49 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/14/2018 4:37:08 PM
swanlinbar   Tuesday, 08/21/18 12:13:49 PM
Re: None
Post # of 190 
Milestone Scientific Provides Business Update for the Second Quarter of 2018
5:11 pm ET August 14, 2018 (Dow Jones) Print
Milestone Scientific Provides Business Update for the Second Quarter of 2018

LIVINGSTON, N.J., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery instruments that provide painless and precise injections, today provided a business update and announced financial results for the second quarter and six months ending June 30, 2018.

Leonard Osser, Interim Chief Executive Officer of Milestone Scientific, commented, "We continue to focus on commercial efforts around the CompuFlo(R) Epidural system. During the second quarter we expanded our network to eight independent distributors covering key markets across the U.S., including the Pacific Northwest, Southeast, Southwest, Midwest, Northwest and Mid-Atlantic regions. We believe our rapid progress is due to our new decentralized sales strategy, whereby we are targeting independent distributors with existing physician and hospital relationships within their respective territories and clinical specialties."

"Last month, we announced that the CompuFlo(R) Epidural System was featured in a prominent peer-reviewed scientific journal. The CompuFlo(R) Epidural System was selected to objectively measure and evaluate the integrity of a third-party epidural simulator. We believe this further illustrates that CompuFlo(R) is becoming accepted as best-in-class for its ability to measure tissue density and accurately identify the tip of the needle in real time."

"We experienced some weakness within our dental division in the second quarter of 2018 due to advance purchases in both China and the U.S. late last year, as well as a manufacturing delay, which has since been resolved. Nevertheless, we did see an increase of approximately 66% in international dental revenue, excluding China, for the second quarter of 2018 versus the same period last year. We anticipate some continued lumpiness in the dental business quarter-to-quarter, due to the timing of orders, but overall, we anticipate our dental division will continue to generate steady growth and maintain solid margins."

Revenue for the three months ended June 30, 2018 was $2.4 million versus $2.5 million for the second quarter of 2017. Domestic sales decreased by approximately $231,000 in 2018. The decrease in revenue was due in part to advanced purchases from Henry Schein in the fourth quarter of 2017, in anticipation of a planned price increase in 2018. Additionally, total revenues during the three months ended June 30, 2018 did not include sales to Milestone China, compared to approximately $356,000 in sales to Milestone China for the three months ended June 30, 2017. International dental revenue excluding China increased approximately $492,000 for the three months ended June 30, 2018 compared to the same period in 2017. Gross profit for the second quarter of 2018 was $1.4 million or 58% of revenue versus $1.7 million or 65% of revenue in the second quarter of 2017. Net loss applicable to common stockholders for the second quarter of 2018 was $(1.3) million, or $(0.04) per share, versus net loss applicable to common stockholders of $(1.5) million, or $(0.05) per share, for the comparable period in 2017.

Revenue for the six months ended June 30, 2018 was $4.2 million versus $6.2 million for the second quarter of 2017. Domestic dental revenue decreased approximately $1.0 million during the six months ended June 30, 2018 as compared to the same period in 2017, of which, approximately $1 million was related to the advanced purchases from Henry Schein in the fourth quarter of 2017. Additionally, total revenues during the six months ended June 30, 2018 did not include sales to Milestone China, compared to approximately $1.4 million in sales to Milestone China for the six months ended June 30, 2017. International dental revenue excluding China increased approximately $407,000 for the six months ended June 30, 2018, compared to the same period in 2017. Gross profit for the first six months of 2018 was $2.6 million or 63% of revenue versus $3.9 million or 63% of revenue in the first six months of 2017. Net loss applicable to common stockholders for the first six months of 2018 was $(3.2) million, or $(0.09) per share, versus net loss applicable to common stockholders of $(2.0) million, or $(0.06) per share, for the comparable period in 2017.

Conference Call

Milestone Scientific's executive management team will host a conference call at 8:30 AM Eastern Time on Wednesday, August 15, 2018 to discuss the Company's financial results for the second quarter ended June 30, 2018, as well as the Company's corporate progress and other developments.

The conference call will be available on the Company's website at www.milestonescientific.com, or via telephone by dialing toll free 800-263-0877 and entering the pass code: 9671500. For those unable to participate at that time, a replay of the call will be archived on the company's website or can be accessed by dialing 888-203-1112 and entering the pass code 9671500. The replay will be available for 90 days.

About Milestone Scientific Inc.

Milestone Scientific Inc. (MLSS) is a biomedical technology research and development company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and instruments for medical, dental, cosmetic and veterinary applications. Milestone's computer-controlled systems are designed to make injections precise, efficient, and virtually painless. Milestone's proprietary DPS Dynamic Pressure Sensing technology(R) is our technology platform that advances the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions for local anesthesia for subcutaneous drug delivery, with specific applications for cosmetic botulinum toxin injections, epidural space identification in regional anesthesia procedures and intra-articular joint injections. For more information please visit our website: www.milestonescientific.com.

Safe Harbor Statement

This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2017. The forward looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

ASSETS June 30, 2018 December 31, 2017

(Unaudited) (Audited)

----------- --------------

Current Assets:

Cash and cash equivalents $ 865,654 $ 2,636,956

Accounts receivable, net 1,840,145 1,535,513

Accounts receivable, from

related party 2,817,990 1,725,450

Note receivable from

financing transaction,

current - 500,000

Prepaid expenses and other

current assets 484,753 436,410

Deferred cost, related party 1,796,036 1,109,671

Inventories, net 2,310,330 3,379,209

Advances on contracts 861,782 697,192

Total current assets 10,976,690 12,020,401

Furniture, fixtures &

equipment, net 105,529 141,760

Patents, net 2,320,392 2,789,748

Note receivable from

financing transaction,

noncurrent - 650,000

Other assets 26,878 26,878

Total assets 13,429,489 15,628,787

LIABILITIES AND STOCKHOLDERS'

EQUITY

Current Liabilities:

Accounts payable $ 1,365,491 $ 853,859

Accounts payable, related

party 1,352,802 1,109,442

Accrued expenses and other

payables 1,937,571 2,287,908

Deferred profit, related

party 636,126 751,500

Deferred revenue, related

party 2,817,990 1,725,450

Total current liabilities 8,109,980 6,728,159

Deferred gain from financing

transaction - 1,400,000

Total liabilities $ 8,109,980 $ 8,128,159

Commitments and Contingencies

Stockholders' Equity

Series A convertible

preferred stock, par value

$.001, authorized 5,000,000

shares, and 7,000 shares

issued and outstanding as of

June 30, 2018 and December

(MORE TO FOLLOW) Dow Jones Newswires

August 14, 2018 17:11 ET (21:11 GMT)

31, 2017 $ 7 $ 7

Common stock, par value

$.001; authorized 50,000,000

shares; 33,660,970 shares

issued, 1,912,503 shares to

be issued and 33,627,637

shares outstanding as of

June 30, 2018; 33,191,571

shares issued, 1,401,247

shares to be issued and

33,158,238 shares

outstanding as of December

31, 2017; 35,571 34,593

Additional Paid in Capital 87,832,358 86,689,084

Accumulated deficit (81,784,998) (78,568,284)

Treasury stock, at cost,

33,333 shares (911,516) (911,516)

Total Milestone Scientific Inc.

stockholders' equity 5,171,422 7,243,884

Noncontrolling interest 148,087 256,744

Total stockholders' equity 5,319,509 7,500,628

Total liabilities and

stockholders' equity $ 13,429,489 $ 15,628,787

MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

Three Months Ended June

30, Six Months Ended June 30,

2018 2017 2018 2017

Product sales, net $ 2,428,498 $ 2,523,750 $ 4,234,103 $ 6,212,738

Cost of products

sold 1,021,573 873,586 1,584,250 2,275,871

Gross profit 1,406,925 1,650,164 2,649,853 3,936,867

Selling,

general and

administrative

expenses 2,821,837 3,082,534 5,840,601 5,790,161

Research and

development

expenses 9,775 120,065 235,592 225,080

Total operating

expenses 2,831,612 3,202,599 6,076,193 6,015,241

Loss from operations (1,424,687) (1,552,435) (3,426,340) (2,078,374)

Other expenses (1,756) (1,024) (3,457) (1,763)

Interest income 1,926 2,154 4,590 2,442

Loss before

provision for

income taxes and

equity in net

losses of equity

investments (1,424,517) (1,551,305) (3,425,207) (2,077,695)

Provision for

income taxes (4,075) (4,664) (15,538) (11,865)

Loss before equity

in net losses of

equity investments (1,428,592) (1,555,969) (3,440,745) (2,089,560)

Earnings (Loss) on

earnings from China

Joint Venture 78,591 15,460 115,374 (28,941)

Net loss (1,350,001) (1,540,509) (3,325,371) (2,118,501)

Net loss

attributable

to

noncontrolling

interests 6,994 61,684 108,657 134,808

Net loss

attributable to

Milestone

Scientific Inc. $(1,343,007) $(1,478,825) $(3,216,714) $(1,983,693)

Net loss per share

applicable to common

stockholders--

Basic (0.04) (0.05) (0.09) (0.06)

Diluted (0.04) (0.05) (0.09) (0.06)

Weighted average

shares outstanding

and to be issued-- 35,297,906 32,399,997 34,939,306 32,122,482

Basic 35,297,906 32,399,997 34,939,306 32,122,482

Diluted

MILESTONE SCIENTIFIC INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Six Months Ended June 30,

2018 2017

Cash flows from operating

activities:

Net loss $ (3,325,371) $(2,118,501)

Adjustments to reconcile net loss

to net cash used in operating

activities:

Depreciation expense 40,762 31,023

Amortization of patents 469,356 35,364

Stock compensation 170,901 237,858

Equity (income) loss on China

joint venture (115,374) 28,941

Inventory reserve 290,349 -

Changes in operating assets and

liabilities:

Increase in accounts

receivable (304,632) (617,347)

Increase (decrease) in

accounts receivable, related

party (1,092,540) 2,358,200

Decrease in other receivables - 10,000

Decrease in inventories 778,530 104,348

Increase to in advances on

contracts (164,590) (150,604)

Decrease (increase) in prepaid

expenses and other current

assets (48,343) (454,562)

Increase in other assets - (9,523)

And so we are told this is the golden age
And gold is the reason for the wars we wage U2
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist